Get started
ReutersReuters

Tempus Introduces xM, An Assay To Monitor Immunotherapy Response For Patients With Advanced Cancers

RefinitivLess than 1 min read
TEM

Tempus AI Inc TEM:

  • TEMPUS INTRODUCES XM, AN ASSAY TO MONITOR IMMUNOTHERAPY RESPONSE FOR PATIENTS WITH ADVANCED CANCERS

North AmericaReutersUS stocks
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news

More news from Reuters